scholarly journals Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study

Urology ◽  
2015 ◽  
Vol 85 (5) ◽  
pp. 1111-1116 ◽  
Author(s):  
Yejin Mok ◽  
Heejin Kimm ◽  
Sang Yop Shin ◽  
Sun Ha Jee ◽  
Elizabeth A. Platz
Author(s):  
Philipp Dahm

This chapter provides a summary of the landmark Scandinavian Prostate Cancer Group Study Number 4 trial of men with clinically localized prostate cancer from the pre–prostate-specific antigen (PSA) era who were randomized to radical prostatectomy versus watchful waiting and were followed long term. With follow-up of more than 20 years, the results favored surgery with regard to prostate cancer mortality.


2017 ◽  
Vol 66 (4) ◽  
pp. 768-772
Author(s):  
Ziyue Wu ◽  
Mihaela Aslan ◽  
Haiqun Lin ◽  
John Ko ◽  
Krishnan Radhakrishnan ◽  
...  

Prostate-specific antigen (PSA) measurements after primary treatment reflect residual tumor burden among men with prostate cancer. Using a mixture model analysis, we identified distinct trajectories of post-treatment PSA measurements and evaluated their associations with prostate cancer mortality. The study sample included 623 US Veterans treated for prostate cancer with curative intent during 1991–1995; 225 men received surgery and 398 men received radiation therapy. Post-treatment PSA measurements over a 2-year period for each patient were evaluated in latent class mixture models using the SAS TRAJ procedure, and groups of men with distinct trajectories of PSA were identified. These groups were then assessed for associations with 10-year prostate cancer mortality using proportional hazards analysis. Analyses identified three distinct groups—representing patterns of both initial values and changes in PSA over time—after surgery (n=172/31/14) and radiation therapy (n=253/103/22). Men in groups with patterns of higher (compared with the group with lowest) PSA values tended to have worse survival experience: HRs for prostate cancer mortality were 3.45 (P=0.18) and 22.7 (P<0.001) for surgery, and 2.70 (P=0.005) and 18.1 (P<0.001) for radiation therapy. The results indicate that PSA measurements after surgery or radiation therapy with curative intent include groups of men with a diverse spectrum of prognosis for prostate cancer mortality. Although contemporary PSA levels are lower than those observed in the study sample, the corresponding trajectory patterns may become evident shortly after the time of diagnosis and treatment.


2009 ◽  
Vol 75 (5) ◽  
pp. 1350-1356 ◽  
Author(s):  
Michael J. Zelefsky ◽  
Weiji Shi ◽  
Yoshiya Yamada ◽  
Marisa A. Kollmeier ◽  
Brett Cox ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (9) ◽  
pp. e025470 ◽  
Author(s):  
Robin W M Vernooij ◽  
Lyubov Lytvyn ◽  
Hector Pardo-Hernandez ◽  
Loai Albarqouni ◽  
Carlos Canelo-Aybar ◽  
...  

ObjectivesTo investigate men’s values and preferences regarding prostate-specific antigen (PSA)-based screening for prostate cancer.DesignSystematic review.Data sourcesWe searched MEDLINE, EMBASE, PsycINFO and grey literature up to 2 September 2017.Eligibility criteriaPrimary studies of men’s values and preferences regarding the benefits and harms of PSA screening.Data extraction and synthesisTwo independent reviewers extracted data and assessed risk of bias with a modified version of a risk of bias tool for values and preferences studies, the International Patient Decision Aid Standards instrument V.3 and the Cochrane Collaboration risk of bias tool.ResultsWe identified 4172 unique citations, of which 11 studies proved eligible. Five studies investigated PSA screening using a direct choice study design, whereas six used decisions aids displaying patient-important outcomes. The direct choice studies used different methodologies and varied considerably in the reporting of outcomes. Two studies suggested that men were willing to forego screening with a small benefit in prostate cancer mortality if it would decrease the likelihood of unnecessary treatment or biopsies. In contrast, one study reported that men were willing to accept a substantial overdiagnosis to reduce their risk of prostate cancer mortality. Among the six studies involving decision aids, willingness to undergo screening varied substantially from 37% when displaying a hypothetical reduction in mortality of 10 per 1000 men, to 44% when displaying a reduction in mortality of 7 per 1000. We found no studies that specifically investigated whether values and preferences differed among men with family history, of African descent or with lower socioeconomic levels.ConclusionThe variability of men’s values and preferences reflect that the decision to screen is highly preference sensitive. Our review highlights the need for shared decision making in men considering prostate cancer screening.Trial registration numberCRD42018095585.


Sign in / Sign up

Export Citation Format

Share Document